ReviewRejuvenation research2013
Neuropharmacological review of the nootropic herb Bacopa monnieri.
Review in Rejuvenation research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 1 synthesis or guideline pooled it, 267 citations in OpenAlex.
- Neuronutraceuticals Combating Neuroinflammaging: Molecular Insights and Translational Challenges-A Systematic Review.Nutrients · 2022Pooled it
- Changes in MoCA scores with sequential administration of Trikatu Cūrṇa and Brahmi Ghṛta in mild cognitive impairment: an exploratory single-arm clinical study.Frontiers in medicine · 2026Trial
- Trial
- Impact of a purported nootropic supplementation on measures of mood, stress, and marksmanship performance in U.S. active duty soldiers.Journal of the International Society of Sports Nutrition · 2018Trial
- Management of cognitive determinants in senile dementia of Alzheimer's type: therapeutic potential of a novel polyherbal drug product.Clinical drug investigation · 2014Trial
- RP-HPLC quantification and separation of isomeric bacosides and exploration of their anti-schizophrenic potential by network pharmacology.RSC advances · 2026Article
- Bacopa monniera: A Promising Phytotherapeutic Approach in Management of Diabetes-Related Complications.Phytotherapy research : PTR · 2026Review
- From Tradition to Translation: A Critical Appraisal ofInternational journal of molecular sciences · 2026Review
- A comprehensive systematic review of human trials investigating herbal treatments for Alzheimer's disease and dementia.Acta neuropsychiatrica · 2026Review
- Phytochemical and Fungal Bioactive Compounds in the "Brain Health Triad": A Narrative Review on Neurostimulating, Neurotrophic, and Neuroprotective Synergy.International journal of molecular sciences · 2026Review
- A to Z of Health: An Evidence-Based Narrative Review of Multivitamin-Multimineral and Nutraceutical Supplementation.Cureus · 2026Review
- Article
- System-Level, Molecular and Cellular Mechanisms of Selected Plant Adaptogens-A Review.Nutrients · 2026Review
- Protective effects ofVeterinary world · 2026Article
- In vivo and in vitro perspectives in Parkinson's disease: Mechanisms and the role of phytomedicine.Journal of food and drug analysis · 2025Review
- Medicinal Plants for Child Mental Health: Clinical Insights, Active Compounds, and Perspectives for Rational Use.Children (Basel, Switzerland) · 2025Review
- Integrated microscopic, HPTLC, and HRM analyses for differentiating Centella asiatica (L.) Urb., Bacopa monnieri (L.) Wettst, and Hydrocotyle umbellata L.Scientific reports · 2025Article
- Bacopaside-I ameliorates motor dysfunction and neurodegeneration in rat model of Parkinson's disease.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Acute Supplementation of Soluble Mango Leaf Extract (ZynamitePharmaceuticals (Basel, Switzerland) · 2025Article
- Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review synthesizes behavioral research with neuromolecular mechanisms putatively involved with the low-toxicity cognitive enhancing action of Bacopa monnieri (BM), a medicinal Ayurvedic herb. BM is traditionally used for various ailments, but is best known as a neural tonic and memory enhancer. Numerous animal and in vitro studies have been conducted, with many evidencing potential medicinal properties. Several randomized, double-blind, placebo-controlled trials have substantiated BM's nootropic utility in humans. There is also evidence for potential attenuation of dementia, Parkinson's disease, and epilepsy. Current evidence suggests BM acts via the following mechanisms-anti-oxidant neuroprotection (via redox and enzyme induction), acetylcholinesterase inhibition and/or choline acetyltransferase activation, β-amyloid reduction, increased cerebral blood flow, and neurotransmitter modulation (acetylcholine [ACh], 5-hydroxytryptamine [5-HT], dopamine [DA]). BM appears to exhibit low toxicity in model organisms and humans; however, long-term studies of toxicity in humans have yet to be conducted. This review will integrate molecular neuroscience with behavioral research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.